Clinical trial
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
NCT00326417 · Medical College of Wisconsin, Other · Completed
Key facts
| NCT number | NCT00326417 |
|---|---|
| Title | Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301) |
| Official title | Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN #0301) |
| Lead sponsor | Medical College of Wisconsin, Other |
| Collaborators | National Heart, Lung, and Blood Institute (NHLBI) NIH Blood and Marrow Transplant Clinical Trials Network National Cancer Institute (NCI) National Marrow Donor Program |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Anemia, Aplastic |
| Intervention type | Drug |
| Interventions | Fludarabine, Cyclophosphamide 150mg, Cyclophosphamide 100mg, Cyclophosphamide 50mg |
| Enrollment | 97 |
| Start date | Jan 1, 2006 |
| Primary completion | Sep 1, 2015 |
| Completion | Jan 1, 2016 |
| First posted | May 16, 2006 |
| Last update posted | Oct 28, 2021 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: